Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GONAL-F vs ANDEMBRY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GONAL-F (follitropin alfa) is a recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and estrogen production in females and spermatogenesis in males.
Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.
Induction of ovulation in anovulatory women with polycystic ovary syndrome (PCOS),Controlled ovarian stimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF),Induction of spermatogenesis in men with hypogonadotropic hypogonadism
Castration-resistant prostate cancer (chemotherapy-naïve or docetaxel-treated),Metastatic castration-resistant prostate cancer
Subcutaneous injection: 75-300 IU once daily for follicular stimulation; individualized based on response.
ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.
Terminal elimination half-life is approximately 24 hours (range 16–32 hours) following subcutaneous administration. This supports once-daily dosing.
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged up to 20-25 hours in patients with moderate to severe hepatic impairment.
Metabolized via hepatic and renal pathways; exact enzymes not fully characterized. Clearance involves proteolytic degradation and renal excretion.
Hepatic via CYP3A4; active metabolites include abiraterone sulfate, abiraterone N-oxide, and abiraterone glucuronide.
Primarily renal (hepatic metabolism and biliary excretion are minor routes). Approximately 80% of the dose is excreted in urine, with less than 20% in feces.
Primarily renal excretion of unchanged drug (approximately 70-80%) and as metabolites (10-15%); biliary/fecal elimination accounts for less than 10%.
Approximately 70–80% bound to plasma proteins, primarily albumin.
Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 0.3–0.6 L/kg, indicating distribution primarily into extracellular fluid.
Volume of distribution is 0.6-0.8 L/kg, indicating distribution into total body water and some tissue binding.
Subcutaneous: approximately 70% (range 60–80%) relative to intravenous administration.
Oral bioavailability is 85-90%; intravenous administration yields 100% bioavailability.
No specific dose adjustments provided; use with caution in severe renal impairment (GFR <30 m L/min).
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease; avoid use.
No specific Child-Pugh based modifications; caution in severe hepatic impairment.
Mild hepatic impairment (Child-Pugh A): no dose adjustment. Moderate hepatic impairment (Child-Pugh B): reduce dose to 320 mg orally twice daily. Severe hepatic impairment (Child-Pugh C): not recommended.
Not indicated for use in children; no established pediatric dosing.
Safety and efficacy not established in pediatric patients (<18 years); no recommended dose.
Not indicated for use in elderly patients; no specific dosing recommendations.
No specific dose adjustment required based on age. Monitor renal function and for increased risk of adverse events (e.g., diarrhea, hyperglycemia) in elderly patients.
GONAL-F should only be used by physicians experienced in fertility treatment. Ovarian hyperstimulation syndrome (OHSS) is a serious, potentially fatal complication. Patients should be monitored for signs of OHSS. GONAL-F may increase the risk of multiple gestation and pregnancy loss.
None.
Ovarian hyperstimulation syndrome (OHSS): can progress to severe form with respiratory distress, oliguria, and thromboembolism,Ovarian torsion,Multiple pregnancy,Ectopic pregnancy,Pulmonary embolism,Ovarian neoplasia (rare),Hypersensitivity reactions including anaphylaxis
Hepatotoxicity, mineralocorticoid excess, cardiovascular events, adrenal insufficiency, and bone marrow suppression.
Hypersensitivity to follitropin alfa or any excipient,High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Sex hormone-dependent tumors (e.g., ovarian, breast, uterine, pituitary),Pregnancy and lactation,Ovarian cyst or enlargement of unknown origin
Hypersensitivity to abiraterone acetate or any component, severe hepatic impairment (Child-Pugh C), and women who are or may become pregnant.
No specific food interactions. Maintain adequate hydration to reduce OHSS risk.
ANDEMBRY can be taken with or without food. However, grapefruit and grapefruit juice may increase trofinetide levels; avoid concurrent consumption. No other significant food interactions reported.
GONAL-F (follitropin alfa) is not indicated for use during pregnancy and has no direct fetal risk as it is administered for ovulation induction prior to conception. However, if inadvertent administration occurs during pregnancy, there is a potential risk of luteal phase defect and multiple gestation. Human data on fetal effects are limited; animal studies show no evidence of teratogenicity at clinically relevant doses. No consistent pattern of malformations has been reported.
Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth restriction. Contraindicated in pregnancy.
It is not known whether follitropin alfa is excreted in human breast milk. Due to its protein nature and high molecular weight (approximately 30 k Da), transfer into milk is likely limited. However, because GONAL-F is typically used in fertility treatments and not during breastfeeding, no specific M/P ratio is available. Caution is advised if use is considered during lactation.
Excreted in human milk; M/P ratio unknown. Potential for serious adverse effects in nursing infant. Contraindicated during breastfeeding.
GONAL-F is contraindicated during pregnancy; therefore, no dosing adjustments during pregnancy are applicable. Treatment should be discontinued if pregnancy is confirmed.
Do not use in pregnancy. No dose recommendations available; contraindicated.
GONAL-F (follitropin alfa) is a recombinant FSH used for ovulation induction and controlled ovarian stimulation. Monitor estradiol levels and follicle growth via ultrasound to adjust dosing and reduce OHSS risk. Use the lowest effective dose. Do not administer if ovarian cyst or enlargement is present. LH supplementation may be needed in hypogonadotropic hypogonadism.
ANDEMBRY (trofinetide) is indicated for the treatment of Rett syndrome. Administer orally twice daily with or without food. Monitor for diarrhea and vomiting, which are common adverse effects; consider dose reduction or temporary discontinuation if severe. Assess liver enzymes and bilirubin before and during treatment due to potential hepatotoxicity. Avoid use in patients with severe hepatic impairment. Do not crush or chew capsules; for patients unable to swallow, sprinkle contents onto soft food and administer immediately.
Inject subcutaneously as directed; rotate injection sites to avoid lipodystrophy.,Report severe pelvic pain, nausea, weight gain, or shortness of breath immediately (OHSS symptoms).,Missed doses can affect cycle; do not double dose without consulting healthcare provider.,Store vials in refrigerator (2-8°C) before mixing; after mixing, use immediately or store refrigerated for up to 28 days.,Avoid pregnancy tests until instructed; false positives may occur from h CG trigger.
Take ANDEMBRY exactly as prescribed, twice daily with or without food.,If you miss a dose, skip it and take the next dose at the regular time; do not double the dose.,Common side effects include diarrhea and vomiting; inform your doctor if these become severe or persistent.,Avoid alcohol while taking this medication as it may increase the risk of liver injury.,Report any signs of liver problems such as yellowing of skin or eyes, dark urine, or abdominal pain.,Do not crush or chew the capsules; if you have trouble swallowing, open the capsule and mix the contents with a small amount of soft food (e.g., applesauce) and take immediately.,Keep this medication out of reach of children and store at room temperature away from moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GONAL-F vs ANDEMBRY, answered by our medical review team.
GONAL-F is a Gonadotropin that works by GONAL-F (follitropin alfa) is a recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and estrogen production in females and spermatogenesis in males.. ANDEMBRY is a Gonadotropin that works by Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GONAL-F and ANDEMBRY depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GONAL-F is: Subcutaneous injection: 75-300 IU once daily for follicular stimulation; individualized based on response.. The standard adult dose of ANDEMBRY is: ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GONAL-F and ANDEMBRY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GONAL-F is classified as Category C. GONAL-F (follitropin alfa) is not indicated for use during pregnancy and has no direct fetal risk as it is administered for ovulation induction prior to conception. However, if ina. ANDEMBRY is classified as Category C. Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth res. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.